Albireo is currently working on several clinical trials. See below for details on the trials we have in progress.
An open-label Phase 3 clinical trial evaluating the long-term safety and efficacy of odevixibat in children with PFIC.
Pivotal Phase 3, double-blind, randomized, placebo-controlled trial which will enroll approximately 200 patients at up to 75 sites globally to evaluate the efficacy and safety of odevixibat in children with biliary atresia who have undergone a Kasai procedure before age three months. BOLD is the largest prospective intervention trial ever conducted in biliary atresia.
Pivotal Phase 3 double-blind, randomized, placebo-controlled global Phase 3 trial of odevixibat in Alagille syndrome to evaluate the safety and efficacy of odevixibat in relieving pruritus in patients with Alagille syndrome.